Given that radiologically isolated syndrome (RIS), in some cases, constitutes a preclinical stage of multiple sclerosis (MS), 1 and based on the great amount of research showing that early initiation of diseasemodifying therapy (DMT) delays the conversion to MS in clinically isolated syndromes (CIS), the debate about the suitability of recommending DMT for RIS patients takes on special importance.
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Given that radiologically isolated syndrome (RIS), in some cases, constitutes a preclinical stage of multiple sclerosis (MS), 1 and based on the great amount of research showing that early initiation of diseasemodifying therapy (DMT) delays the conversion to MS in clinically isolated syndromes (CIS), the debate about the suitability of recommending DMT for RIS patients takes on special importance.
There are two crucial questions to be addressed in this debate. The first point refers to whether the benefitrisk ratios of current DMT would actually be favorable among RIS patients. Emerging data suggest that in RIS, the clinical and pathological damage of magnetic resonance imaging (MRI) lesions might be compensated by more efficient reparative mechanisms, [2] [3] [4] [5] which is in accordance with current data showing that almost 7 out of 10 RIS patients do not develop clinical relapses within a 5-year period of follow-up. 1 Furthermore, it is not yet known whether most RIS patients will ever develop clinical relapses. In this scenario, very high "number needed to treat to benefit (NNTB)" would be expected; that is, a high number of RIS patients need to be treated with a given DMT rather than placebo to avoid the conversion to definite MS over time. In clinical settings where there is a high NNTB, unfavorable benefit-risk ratios in which the expected harms outweigh possible benefits are also expected. Although one might reasonably argue that rigorous enrollment of RIS patients based on the presence of the most important known predictors of evolution to MS (e.g. spinal cord lesions) 1,6 could provide a solution to this issue, there are clearly insufficient data to accurately narrow down the RIS subjects who are at higher risk of developing a future demyelinating clinical event. In this context, what would be the factors to select those RIS patients for DMT? Should all RIS patients without spinal cord lesions be excluded from RIS trials?
The second point refers to the validity of the clinical and radiological measures of interest that could be used as primary endpoints or surrogate markers in RIS trials:
1. Time to conversion to clinically definite MS as primary endpoint. RIS natural history seems to be radically different from CIS, in which the majority of cases with abnormal MRI are well known to develop clinically definite MS. 2. The follow-up periods of RIS studies are relatively short, and hence, the long-term risk of RIS for developing clinical MS is largely unknown. 5 Moreover, in contrast to MS and CIS patients, the absence of a definable clinical event makes it impossible to establish the disease duration among RIS patients and, thus, there is a possibility that the disease duration in some RIS patients is actually much longer than in others. All of this raises questions as to whether the time to conversion to clinically definite MS would be a valid primary endpoint for RIS clinical trials as if they were CIS patients.
MRI markers as surrogates for clinical
relapses. Recent MS studies provide evidence that treatment effects on new T2 MRI lesions can predict long-term effects on relapses. 7, 8 However, given the aforementioned potential capacity of RIS to repair, 2-5 the validity of MRI metrics (new T2 lesions) as surrogates for clinical outcomes in RIS clinical trials is not established.
Expanded Disability Status Scale (EDSS) to
assess clinical disability. The clinical picture observed in RIS patients is characterized by null physical disability, but high rates of cognitive and psychiatric symptoms, 9, 10 which are not adequately reflected in the EDSS. Therefore, EDSS does not seem to be a valid tool to quantitatively assess the RIS clinical situation.
In summary, no data are available at the time of writing this controversy to support the recommendation of DMT for RIS patients. In addition, we question whether RIS treatment should really be the next step in RIS research. On the contrary, we believe that we should focus on many unsolved questions (e.g. what is the 10-or 15-year risk of progression or of a clinical relapse event? Is there a "pathological" brain volume C Lebrun loss rate over time in RIS patients? Can the rate of RIS brain volume loss be a herald of future disability or of cognitive worsening?) The improved understanding of RIS as an entity would provide clinicians with more tangible evidence on which to base the decision whether or not to start DMT in individual RIS patients. Until then, RIS as an entity requires much better characterization before starting DMT.
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Radiologically isolated syndrome should be treated with disease-modifying therapy -Commentary Christine Lebrun
In this issue, D Okuda and A Labiano-Fontcuberta, together with J Benito-Leon, discuss the interesting issue of treating patients with radiologically isolated syndrome (RIS). This question alone raises the big issue of recognizing that this syndrome exists.
In real-life practice, we should be able to identify people showing brain and spinal magnetic resonance imaging (MRI) fulfilling dissemination in space criteria, who have no history of symptoms of multiple sclerosis (MS) and a strictly normal neurological examination. 1, 2 Before asking about treatment, neurologists must ask specific questions about the diagnosis of RIS. Since the publications of the first French 3 and Turkish-American 2 RIS cohorts and the identification of a new acronym with specific diagnostic criteria, 1 a lot has been done to find evidence to push RIS to the very left limit of the demyelinating diseases spectrum. The
